Should I buy Vaxart stock in 2025?

What is Vaxart?

What is the price of Vaxart stock?

The price of Vaxart stock is rising this week. Currently trading at $0.4673, VXRT is up by $0.0173 (+3.84%) over the last 24 hours, though it has edged down by 0.82% over the past week. Vaxart’s market capitalization stands at $106.65 million, with a three-month average trading volume of 1.89 million shares. As the company is not yet profitable, its P/E ratio is not applicable, and there is no dividend yield. The stock exhibits a high beta of 1.53, indicating above-average volatility—an important consideration for investors in the UAE market seeking dynamic opportunities.

Our full analysis of the Vaxart stock

Having conducted a thorough review of Vaxart’s latest financial disclosures, alongside a deep dive into its equity performance and sector standing over the last three years, our proprietary screening—integrating advanced financial, technical, and peer-comparison analytics—yields a highly nuanced perspective. The synthesis underscores multiple factors working in favor of Vaxart’s strategic agility, innovation profile, and potential for outsized returns. So, why might Vaxart stock once again become a strategic entry point into the growth-driven biotechnology sector as we head into 2025?

Recent Performance and Market Context

Over the past year, Vaxart (NASDAQ: VXRT) has navigated a challenging environment for clinical-stage biotechs, with pronounced volatility. As of May 30, 2025, the stock traded at $0.4673, marking a robust intraday gain of +3.84%. However, it has experienced a drawdown of -43% year-on-year and -22.1% over six months—a pattern reflective of sector-wide consolidation and sentiment recalibration in the wake of 2024’s risk-off posture.

Despite these numbers, several positive signals have appeared recently:

• Major Phase Progression: The FDA lifted a hold for Vaxart’s pivotal COVID-19 Phase 2b trial, enabling dosing of 10,000 participants—a vital endorsement of both safety and efficacy prospects.
• Pipeline Momentum: Completion of enrollment for the norovirus Phase 1 trial (results anticipated mid-2025) and a 100% protective effect of Vaxart’s avian flu vaccine in preclinical furet models highlight tangible pipeline progress.
• Management Upgrade: The strategic appointment of Jeroen Grasman as CFO in May 2025 adds financial stewardship and operational rigor at a critical juncture.

Macro and sector tailwinds remain in place. The global health innovation cycle is robust, governments are actively supporting next-gen vaccine platforms, and the region’s (AE) emphasis on healthcare resilience further sharpens the relevancy of companies like Vaxart.

Technical Analysis

Turning to the technical structure, Vaxart is displaying constructive signals of accumulation and possible trend reversal:

• Momentum Indicators: The 14-day RSI stands at 55.83, lingering in neutral territory—highlighting the absence of overbought conditions and offering headroom for upward price movement. The MACD remains marginally negative (0.02), but poised for a potential positive crossover.
• Moving Averages: The stock now sits above its key near-term averages, with the 20-day MA ($0.44) and 50-day MA ($0.42) flashing buy signals. These levels suggest short- to mid-term momentum could be shifting bullishly.
• Support and Resistance: $0.41 acts as a durable support, while $0.49 remains the proximate resistance—any decisive close above this level may serve as confirmation of a new bullish phase.
• ADX of 20.57: Implies there is room for a directional trend to assert itself, especially as fundamental catalysts approach.

In summary, Vaxart’s technical landscape, while still forming a base, seems to favor accumulation at these levels, setting the stage for upward movement should positive clinical or partnership newsflow materialise.

Fundamental Analysis

A closer look at fundamentals illuminates unique, scalable strengths:

• Explosive Revenue Acceleration: Q1 2025 revenue surged to $20.9M—an 857% increase from the previous year—underscoring both increased government contracts and pipeline validation.
• Net Loss Reduction: The net loss narrowed to -$15.6M (vs -$24.4M), and EPS improved meaningfully. While not yet profitable, the trajectory is distinctly positive.
• Cash Runway: With $41.9M in cash and equivalents, Vaxart is financed through at least Q1 2026—a critical buffer to weather sector volatility and fund key readouts.
• Attractive Valuation Ratios: Price/Sales (2.14x) and Price/Book (2.34x) reflect modest expectations relative to the company’s pipeline optionality and technology platform.
• Proprietary Moat: The VAAST oral vaccine platform is a significant differentiator, offering needle-free, shelf-stable formulations—major logistical and distribution advantages with global healthcare relevance.
• Diversified Pipeline: Spanning COVID-19, norovirus, influenza (seasonal & avian), and HPV, the pipeline is broad-based and positioned for multi-year optionality.
• Strategic Backing: Substantial government partnership (BARDA contract of up to $460M) affirms technology viability and provides direct, non-dilutive capital.

These factors, in concert, underline that fundamentals more than justify renewed investor interest at current levels.

Volume and Liquidity

Trading activity provides a strong signal of market confidence and institutional attention:

• Robust Volume: With a 3-month average daily volume of 1.89M shares, liquidity is sufficient for institutional participation and reflects active market engagement—critical for both price discovery and responsive trading.
• Favorable Float: 222.14M shares in public float ensure vibrant price dynamics and the potential for significant re-rating should sentiment or data shift positively.

This liquidity profile is particularly attractive for investors looking to position before inflection-point catalysts, offering both flexibility and risk mitigation.

Catalysts and Positive Outlook

Looking forward, the mid- to late-2025 period is populated with high-conviction catalysts likely to amplify investor attention:

• Major Data Releases:
• Topline results from the COVID-19 Phase 2b trial (10,000 participants), considered a “must watch” event by sector analysts.
• Norovirus Phase 1 data release expected mid-year—a potential pipeline accelerator.
• Peer-reviewed publication of avian flu vaccine data (notably 100% protection in furet models), reinforcing Vaxart’s platform credibility.
• Potential Partnerships/Strategic Funding: Ongoing discussions with government and private entities could unlock substantial capital, extending runway and enabling portfolio expansion.
• Market Context: The biotechnology sector is entering a new phase of risk-appetite, underpinned by regulatory facilitation and renewed investor focus on innovative vaccine platforms. Global interest in needle-free technologies and pandemic resilience are aligned with Vaxart’s unique value proposition.

Analysts remain highly constructive: the consensus “Strong Buy” rating, with a median 12-month price target of $3.00 (implying a +542% potential upside), clearly reflects anticipated business progress and revaluation.

Investment Strategies

Various entry strategies present themselves for this advanced-stage, catalyst-rich biotech stock:

• Short-term: Tactical traders could consider positioning around key technical support ($0.41) and ahead of expected binary events (e.g., norovirus trial results). The current price—also just below major resistance ($0.49)—makes for an attractive risk/reward inflection point.
• Medium-term: Investors seeking higher conviction might leverage the momentum building up to the large-scale COVID-19 data release and potential partnership announcements, with the expectation of significant upside repricing as fundamental news materializes.
• Long-term: For those with a higher risk appetite, exposure to Vaxart’s differentiated oral vaccine technology within a diversified portfolio could be seen as a unique play on global health innovation. The platform’s inherent scalability and pipeline diversity present multi-year compounder potential.

Optimal positioning may be achieved by entering positions during current consolidation phases or incrementally increasing exposure ahead of headline clinical readouts.

Is it the Right Time to Buy Vaxart?

Vaxart exhibits a compelling blend of technical stabilization, fundamental momentum, and imminent catalysts. With its differentiated oral vaccine platform, explosive revenue growth, solid liquidity, and deepening management experience, the company stands out amid the early-stage biotech landscape. Its generous government backing and imminent clinical readouts place it at the center of investor focus for the coming quarters.

While acknowledging typical sector risks—including regulatory, clinical, and funding dynamics—the undeniable upside potential and high analyst conviction indicate that Vaxart seems to represent an excellent opportunity for investors seeking asymmetric returns in healthcare innovation in 2025. For those researching high-potential plays within the global biotechnology sector, the stock merits very serious consideration as it appears poised to enter a new bullish phase driven by both technical and fundamental strengths.

In summary, the convergence of technical base-building, operational milestones, and a pipeline with transformative potential suggests Vaxart may soon reassert itself as an alpha-generating component within diversified growth-oriented portfolios—an opportunity investors will want to watch very closely as the sector re-rates.

How to buy Vaxart stock in the UAE?

Buying Vaxart (VXRT) stock online is both simple and secure when using a regulated broker based in the UAE or offering international access. Investors typically have two main ways to gain exposure: direct spot buying, where you purchase and own the stock outright, or trading via CFDs (Contracts for Difference) to speculate on price movements with leverage. Both routes offer flexibility to suit your investment style. If you want to compare UAE-compliant brokers offering Vaxart stock and CFDs, a comprehensive comparison tool is provided further down this page.

Spot Buying

A spot (or cash) purchase means you buy Vaxart shares directly on the US NASDAQ exchange and become a registered shareholder. UAE brokers generally charge a fixed commission for each order, often ranging from AED 15 to AED 40 per trade, or about $4–$10 in USD.

Example: Spot Purchase Scenario

With Vaxart trading at $0.4673 per share, a $1,000 investment (after a typical $5 fee) would allow you to buy approximately 2,126 shares ($995 / $0.4673 ≈ 2,126 shares).
Gain scenario: If the Vaxart share price climbs by 10% to $0.514, your investment would now be worth $1,100.
Result: That’s a $100 gross gain, representing a +10% return on your initial stake (excluding currency fluctuations and taxes).

Trading via CFD

CFD (Contract for Difference) trading allows you to speculate on Vaxart’s share price without owning the shares themselves. Instead, you open a position with a broker, usually paying via the spread (the difference between buy/sell price) and potential overnight financing fees if you hold the position for several days. CFD platforms often allow leverage.

Example: CFD Trading Scenario

With $1,000 and 5x leverage, you gain exposure to $5,000 worth of Vaxart shares.
Gain scenario: If Vaxart stock rises by 8%, your contract is now worth 8% × 5 = 40% gain on your initial outlay.
Result: You make a $400 gain on your $1,000 stake (excluding any spreads or overnight fees).

Final Advice

Before investing in Vaxart, it’s important to compare brokers’ costs, terms, and access to US markets. Each investor’s best approach depends on their financial goals, whether seeking long-term ownership via cash purchase or short-term trading with CFDs. To help you get started, a detailed broker comparison can be found further down the page, so you can choose the right platform for your needs.

Our 7 tips for buying Vaxart stock

The latest news about Vaxart

Vaxart posted a remarkable revenue surge for Q1 2025, up 857% year-over-year to $20.9 million. The company’s latest earnings report shows not only explosive revenue growth but also a considerable reduction in net loss, now $15.6 million compared to $24.4 million a year ago. Per-share loss was halved to $0.07. This trend demonstrates prudent cost management and signals operational improvement, which is particularly encouraging for investors in high-potential biotechnology, including those from the AE region seeking diversification into fast-growing US healthcare innovators.

Vaxart’s Phase 2b COVID-19 vaccine trial resumed following regulatory clearance, with dosing expected in Q2 2025. After a previous clinical hold, regulatory authorities have now allowed the large-scale Phase 2b oral COVID-19 trial with 10,000 participants to proceed, and subject dosing is anticipated imminently. For AE-based analysts, this regulatory progress is a clear de-risking signal, especially as oral vaccines answer both logistical and public-health needs that closely align with GCC regional vaccine accessibility and distribution priorities.

Vaxart secured major US government backing, receiving $85.6 million out of a possible $460.7 million for oral vaccine R&D. Support from the US Biomedical Advanced Research and Development Authority (BARDA) underscores the strategic importance of Vaxart’s technology, with BARDA funding earmarked through Project NextGen. This healthy inflow of non-dilutive capital strengthens cash reserves—now at $41.9 million—extending operations into early 2026. For AE investors and institutions, partnerships with such credible agencies offer reassurance on both stability and the company’s regulatory credibility.

Recent technical analysis signals have shifted to “Buy” on short-term moving averages, reflecting renewed market interest. Both the 20-day and 50-day moving averages have turned bullish, offering “Buy” signals, even as longer-term indicators remain cautious. The stock’s intraday gain of 3.84% last session further highlights the possibility of short-term momentum, with support at $0.41 and resistance at $0.49. Technical setups like this frequently precede rebounds in sentiment, which could attract traders and institutions seeking tactical entry points, including those in the AE looking for dip opportunities in US biopharma.

Industry analysts maintain a “Strong Buy” consensus with a $3.00 price target, reflecting confidence in upside potential. The consensus 12-month target offers more than 500% potential upside from current levels, underscoring broad optimism anchored in Vaxart’s differentiated oral vaccine platform, diversified pipeline, and strong governmental partnerships. These factors are especially relevant for AE stakeholders eager to identify next-generation healthcare plays with the potential for technology transfer or future regional distribution, given Vaxart’s focus on ambient-stable, easy-to-administer therapies well-suited to international public health infrastructures.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.